Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vireo Growth Inc.GDNSF · Entity 5397 | CHIEF MEDICAL OFFICER | March 15, 2022 | March 18, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vireo Growth Inc.
Report date March 15, 2022 · Filed March 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table I · non-derivative | Direct | 99,511 |
Reported balance
After 2022-03-15 transaction · row 1
1 source rowRow 1 · 2022-03-15 · Grant · Acquired 99,511 · Balance 99,511 F1: Restricted Stock Units vest in three equal annual installments beginning on March 31, 2023; each vested tranche becomes Subordinated Voting Shares. |
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2032-03-14 | Direct | 239,907 |
Reported balance
After 2022-03-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-15 · Grant · Acquired 239,907 · Balance 239,907 F2: Options vest as follows: 25% on March 31, 2023, 6.25% on June 30, 2023 and the last day of each calendar quarter thereafter until 100% are vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units vest in three equal annual installments beginning on March 31, 2023; each vested tranche becomes Subordinated Voting Shares.
F2: Options vest as follows: 25% on March 31, 2023, 6.25% on June 30, 2023 and the last day of each calendar quarter thereafter until 100% are vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2022 Filed Mar 18, 2022 18:32 UTC | Vireo Growth Inc. GDNSF · Entity 5397 | GrantStock Options · Derivative | 239,907 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001415889-22-003170 · form4-03182022_110318.xml · derivative · entry 2 Dahmer Stephen · CIK 0001836868 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,907 Underlying: Subordinate Voting Shares · 239,907 shares Expires 2032-03-14 F2 · derivative.exercise_date: Options vest as follows: 25% on March 31, 2023, 6.25% on June 30, 2023 and the last day of each calendar quarter thereafter until 100% are vested. Read SEC document |
| March 15, 2022 Filed Mar 18, 2022 18:32 UTC | Vireo Growth Inc. GDNSF · Entity 5397 | GrantRestricted Stock Units | 99,511 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003170 · form4-03182022_110318.xml · nonDerivative · entry 1 Dahmer Stephen · CIK 0001836868 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,511 F1 · shares: Restricted Stock Units vest in three equal annual installments beginning on March 31, 2023; each vested tranche becomes Subordinated Voting Shares. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.